data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Xeris Biopharma Holdings
(NASDAQ:XERS)
1.61
00
At close: Jun 27
1.65
0.0400[2.48%]
PreMarket: 7:15PM EDT
15 minutes delayed
Day High/Low- - -
52 Week High/Low1.25 - 4.98
Open / Close- / -
Float / Outstanding121.1M / 135.5M
Vol / Avg.- / 1.9M
Mkt Cap218.2M
P/E-
50d Avg. Price2.07
Div / Yield-
Payout Ratio-
EPS-0.25
Total Float121.1M

Xeris Biopharma Holdings (NASDAQ:XERS), Quotes and News Summary

Xeris Biopharma Holdings (NASDAQ: XERS)

Day High/Low- - -
52 Week High/Low1.25 - 4.98
Open / Close- / -
Float / Outstanding121.1M / 135.5M
Vol / Avg.- / 1.9M
Mkt Cap218.2M
P/E-
50d Avg. Price2.07
Div / Yield-
Payout Ratio-
EPS-0.25
Total Float121.1M
Benzinga - Jun 16, 2022, 6:58AM
Benzinga - May 12, 2022, 4:18PM
Benzinga - May 11, 2022, 7:09AM
Benzinga - Apr 28, 2022, 9:49AM
Benzinga - Apr 28, 2022, 7:00AM
Benzinga - Mar 16, 2022, 6:49AM
Benzinga - Mar 10, 2022, 7:20AM
Benzinga - Feb 16, 2022, 5:21AM
Benzinga - Jan 31, 2022, 7:07AM
Benzinga - Jan 18, 2022, 10:18AM
Benzinga - Jan 18, 2022, 7:14AM
Benzinga - Jan 13, 2022, 8:57AM
Benzinga - Jan 3, 2022, 7:03AM
Benzinga - Dec 31, 2021, 9:13AM
Benzinga - Dec 31, 2021, 9:00AM
Benzinga - Dec 31, 2021, 8:07AM
load more
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.250-0.250 0.0000
REV23.590M21.910M-1.680M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Xeris Biopharma Holdings Questions & Answers

Q
How do I buy Xeris Biopharma Holdings (XERS) stock?
A

You can purchase shares of Xeris Biopharma Holdings (NASDAQ: XERS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Xeris Biopharma Holdings's (XERS) competitors?
A

There are no as such competitors for Xeris Biopharma Holdings.

Q
What is the target price for Xeris Biopharma Holdings (XERS) stock?
A

The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by Craig-Hallum on Thursday, April 28, 2022. The analyst firm set a price target for 6.50 expecting XERS to rise to within 12 months (a possible 303.73% upside). 7 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Xeris Biopharma Holdings (XERS)?
A

The stock price for Xeris Biopharma Holdings (NASDAQ: XERS) is $1.61 last updated June 27, 2022, 8:00 PM UTC.

Q
Does Xeris Biopharma Holdings (XERS) pay a dividend?
A

There are no upcoming dividends for Xeris Biopharma Holdings.

Q
When is Xeris Biopharma Holdings (NASDAQ:XERS) reporting earnings?
A

Xeris Biopharma Holdings’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Xeris Biopharma Holdings (XERS) going to split?
A

There is no upcoming split for Xeris Biopharma Holdings.

Q
What sector and industry does Xeris Biopharma Holdings (XERS) operate in?
A

Xeris Biopharma Holdings is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.